CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Cephalon Inc. v. Hospira Inc.

1:13-cv-02094

πŸ“‘ 5G SEP β€’ ETSI Declared

Overview

Case Number 1:13-cv-02094
Filing Date 2013-12-26
Status Terminated
Termination Date 2017-06-29
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Hospira Inc. Operating Company

Represented By

3 Attorneys Listed

Samantha G. Wilson

Young, Conaway, Stargatt & Taylor LLP

Tel: +1 (302) 571-5018

Rodney Square, 1000 North King Street

Monte Terrell Squire

Duane Morris LLP

Tel: +1 (302) 657-4918
Fax: +1 (302) 397-2543

1201 North Market Street, Suite 501

Melanie K. Sharp

Young, Conaway, Stargatt & Taylor LLP

Tel: +1 (302) 571-6681
Fax: +1 (302) 571-1253

Rodney Square, 1000 North King Street

Plaintiff

Cephalon Inc. Operating Company

Represented By

9 Attorneys Listed

Nicholas K. Mitrokostas

Email: nicholas.mitrokostas@allenovery.com

Karen Elizabeth Keller

Shaw Keller LLP

Tel: +1 (302) 298-0700

1105 North Market Street, 12th Floor, Wilmington, DE 19801

Jonathan A. Auerbach

UNDELIVERABLE EMAIL 9/28/2016

Jeff Castellano

DLA Piper LLP

Tel: +1 (302) 468-5671

1201 N. Market St., Suite 2100

Emily L. Rapalino

Email: erapalino@goodwinlaw.com

David M. Hashmall

Email: dhashmall@goodwinlaw.com

Daryl L. Wiesen

Email: dwiesen@goodwinlaw.com

Calvin E. Wingfield , Jr.

Email: cwingfield@goodwinlaw.com

John W. Shaw

Shaw Keller LLP

Tel: +1 (302) 298-0701

I.M. Pei Building, 1105 North Market Street

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 10 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts Counterparts in force
πŸ›οΈ
USPTO PTAB Trials 1 proceeding
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (10): πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (1 found):
PTAB: 1
USPTO PTAB Trial 2014-12-24
IPR2015-00503

AGILA SPECIALTIES INC. v. Cephalon, Inc.

U.S. Continuation Sibling (8436190)
Status: Terminated-Settled
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Standard Essential Patent (SEP) & FRAND Intelligence

5G SEP β€’ ETSI Declared High-Probability SEP Action

Essential standard specifications, SSO declaration status, and FRAND antitrust defense evaluation

FRAND Encumbered
Essential Standard 4G / 5G LTE Generation: 5G
Standard Setting Org (SSO) ETSI / 3GPP Essential specification under ETSI / 3GPP governance
FRAND Commitment Committed Fair, Reasonable & Non-Discrim.
Known Patent Pools Avanci / Sisvel / Via Licensing Coverage Applicable Declarant: Sharp

Injunction Restrictions & FRAND Defense Leverage (CJEU Huawei v. ZTE Framework)

Permanent Injunction Restricted

Asserted by recognized SEP declarant. Under the CJEU Huawei v. ZTE test, injunctions are barred if the defendant qualifies as a willing licensee.

βœ“ Patentee bound by SSO IPR Policy (ETSI Annex 6 / IEEE Patent Policy).
βœ“ Right to demand global FRAND portfolio determination.
βœ“ Non-discrimination defense: check licensing terms offered to competing implementers.

Patents Involved

2 Patents

There are 2 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US8445524
Solid forms of bendamustine hydrochloride
Filed: 2011-11-22
Issued: 2013-05-21
Active (5.0 yrs remaining)
Expires: 2031-11-22
US8436190
Bendamustine pharmaceutical compositions
Filed: 2006-01-12
Issued: 2013-05-07
Active (3.9 yrs remaining) +1748d PTA
Expires: 2030-10-26

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Active Threat

Active Threat β€” Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting truncation noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

5

Dispositive

1

Granted

0

Denied

0

Pending / Review

1

Motions by Category

Procedural / Extension Motion 2 Claim Construction / Markman Filing 2 Motion to Dismiss 1

Key Dispositive Motions & Rulings

Motion to Dismiss Pending
Remark : Cases are consolidated for all purposes. All future filings shall be made only in lead CA 13-2046 GMS, including documents relating to the pending Moti...
Entry #β€” • 2014-11-24
Claim Construction / Markman Filing Pending
SO ORDERED - Proposed Scheduling Order filed by Cephalon, Inc. Setting Scheduling Order Deadlines: Cases are consolidated for all purposes. All future filings s...
Entry #β€” • 2014-11-24
Claim Construction / Markman Filing Pending
Minute Entry for proceedings held before Judge Gregory M. Sleet - Scheduling Conference held on 10/30/2014. These cases are consolidated for all purposes. Couns...
Entry #β€” • 2014-10-31
Procedural / Extension Motion Pending
SO ORDERED, re 7 STIPULATION TO EXTEND TIME to answer, move or otherwise respond to the Complaint to January 28, 2014 filed by Hospira Inc., Cephalon Inc. Set/R...
Entry #β€” • 2014-01-17
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME to answer, move or otherwise respond to the Complaint to January 28, 2014 - filed by Cephalon Inc., Hospira Inc.. (Squire, Monte) (En...
Entry #7 • 2014-01-16 Document →

Docket Entries

(60 total)
Pleading / Complaint

COMPLAINT - filed against Hospira Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400.00, receipt number 0311-1432036.) - filed by Cephalon Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet)(rwc) (Entered: 12/27/2013)

Entry #1 • 2013-12-26
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (rwc) (Entered: 12/27/2013)

Entry #2 • 2013-12-26
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 11/20/13. Date of Expiration of Patent: 3/26/29.Thirty Month Stay Deadline: 5/20/2016. (rwc) (Entered: 12/27/2013)

Entry #3 • 2013-12-26
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 8,445,524 B2; US 8,436,190 B2. (rwc) (Entered: 12/27/2013)

Entry #4 • 2013-12-26
1

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Teva Pharmaceuticals Industries Ltd. for Cephalon Inc. - filed by Cephalon Inc. (rwc) (Entered: 12/27/2013)

Entry #5 • 2013-12-26
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc